Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 19/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.40 |
| ▸ | IL6 | P05231 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1716295 | 1.00 | NR3C1 (0.41) | NR3C1CYP3A4NR3C2IL6CYP2D6 | |
| SCHEMBL1716293 | 1.00 | NR3C1 (0.41) | NR3C1CYP3A4NR3C2IL6CYP2D6 | |
| SCHEMBL1492598 | 0.89 | NR3C1 (0.50) | NR3C1CYP3A4NR3C2IL6CYP2D6 | |
| SCHEMBL1716493 | 0.89 | NR3C1 (0.50) | NR3C1CYP3A4NR3C2IL6CYP2D6 | |
| SCHEMBL1492551 | 0.89 | NR3C1 (0.50) | NR3C1CYP3A4NR3C2IL6CYP2D6 | |
| SCHEMBL1492589 | 0.85 | NR3C1 (0.38) | NR3C1CYP3A4NR3C2CYP2C9CYP2C19 | |
| SCHEMBL1716235 | 0.83 | NR3C1 (0.45) | NR3C1NR3C2PGR | |
| SCHEMBL1492579 | 0.83 | NR3C1 (0.45) | NR3C1NR3C2PGR | |
| SCHEMBL1716234 | 0.83 | NR3C1 (0.45) | NR3C1NR3C2PGR | |
| SCHEMBL1492540 | 0.82 | NR3C1 (0.46) | NR3C1CYP3A4NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2300472-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885CYP3A4 360/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.